Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Piramal Eyes 20% Pharma Stake Sale

Looking To Raise Funds For Growth Through Acquisitions

Executive Summary

Piramal Enterprises, one of India’s biggest conglomerates, has said it is looking to sell up to a 20% stake in its Piramal Healthcare business to raise funds for spurring growth of the division through acquisitions.

You may also be interested in...



Piramal Pharma Stake Sale On Track

Piramal Enterprises, which is in the process of fundraising for its pharma business, says it is well geared to cater to evolving requirements in the sector amid COVID-19 given its global manufacturing footprint with a strong compliance record. Pharma, the Indian firm’s management maintains, is one of the ‘safest and most resilient’ industries in the current uncertainty.

Piramal Pharma Stake Sale On Track, Gains Seen For Contract Business Amid Pandemic

Piramal Enterprises, which is in the process of fund raising for its pharma business, says it's well geared to cater to evolving requirements in the sector amid COVID-19 given its global manufacturing footprint with a strong compliance record. Pharma, the Indian firm’s management maintains, is one of the ‘safest and most resilient’ industries in the current uncertainty.

Piramal Profits As It Sheds DRG To Clarivate For $950m

An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel